The new chief medical executive of University of Texas MD Anderson Cancer Center is committed to a collaborative approach—both inside and outside the organization.

The trial, conducted by The University of Texas MD Anderson Cancer Center, showed a favorable safety profile and injection feasibility as well as a median overall survival (mOS) of 23 months from the ...